cdc7-in-1

Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.

Cdc7-IN-15 (Example 108) 是 cdc7激酶抑制剂，具有用于癌症研究的潜力。

Cdc7-IN-17 是CDC7的有效抑制剂，IC50值小于10 μM，可用于癌症研究。

(S)-Cdc7-IN-18, a potent CDC7 inhibitor, effectively impedes the overactivation of MCM2, a crucial tumor cell marker, induced by huCdc7 overexpression. Consequently, it inhibits the aberrant proliferation of tumor cells. This compound, exhibits promise for cancer disease research [1].

Cdc7-IN-10 是一种 Cdc7 的高效抑制剂 (IC50≤1 nM)，能够用于增殖性疾病的研究。

Cdc7-IN-11 是一种 Cdc7 的高效抑制剂 (IC50≤1 nM)，能够用于增殖性疾病的研究。

Cdc7-IN-12 (compound 1) 是 CDC7的有效抑制剂(IC50为 <1 nM)，在癌症研究中具有潜力。Cdc7-IN-12 在人结肠癌细胞COLO205 中表现出抗增殖活性，IC50为 100-1000 nM。

Cdc7-IN-19 (compound 1-1) 是一种有效的CDC7抑制剂，对 Cdc7 DBF4 酶的IC50为 1.49 nM。

Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].

Cdc7-IN-14 (compound 82) is a highly potent inhibitor of CDC7, demonstrating an IC50 value of less than 1 nM. This compound, Cdc7-IN-14, exhibits promising potential for cancer research [1].

Cdc7-IN-18 (compound 1-2) is a highly effective inhibitor of the CDC7 enzyme. It has an IC 50 value of 1.29 nM for the Cdc7 DBF4 enzyme. In addition, this compound exhibits strong antiproliferative activities, with an IC 50 value of 53.62 nM in COLO205 cells [1].

LY3143921 ((S)-Example 2) 具有广泛的体外抗癌活性，是口服有效的CDC7激酶抑制剂。

Cdc7-IN-9 是可以用于癌症研究的，Cdc7的有效抑制剂。

Cdc7-IN-8, a potent inhibitor, targets Cdc7, a serine threonine kinase responsible for activating MCM promotion through phosphorylation of the microchromosome maintenance protein (MCM protein). MCM protein, an essential component of DNA replication initiation, plays a crucial role. Cdc7-IN-8 holds promise in cancer disease research (WO2021032170A1, compound 1-1 1-2) [1].

LY3143921 ((S)-Example 2) hydrate 是一种具有口服活性的 CDC7激酶抑制剂。LY3143921 hydrate 表现出广泛的体外抗癌活性。